Nuvectis Pharma (NVCT)
(Real Time Quote from BATS)
$6.50 USD
+0.20 (3.18%)
Updated Aug 13, 2024 10:40 AM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NVCT 6.50 +0.20(3.18%)
Will NVCT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NVCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NVCT
Wall Street Analysts See a 229.34% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?
Down -36.49% in 4 Weeks, Here's Why You Should You Buy the Dip in Nuvectis Pharma, Inc. (NVCT)
NVCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for July 10th
Here's Why Momentum in Nuvectis Pharma, Inc. (NVCT) Should Keep going
Zacks.com featured highlights Corsair Gaming, Nuvectis Pharma and WisdomTree
Other News for NVCT
Nuvectis Pharma: Strong Buy Rating on Solid Financials and Promising Oncology Pipeline
Nuvectis Pharma reports Q2 results
Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights
Nuvectis Pharma reports Q2 net loss $4.4M vs. $5.8M last year
7 Penny Biotech Stocks to Triple Your Investment